Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity
Open Access
- 1 June 2003
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (6) , 2795-2796
- https://doi.org/10.1128/jcm.41.6.2795-2796.2003
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Faculty Opinions recommendation of Staphylococcus aureus resistant to vancomycin--United States, 2002.Published by H1 Connect ,2002
- In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 2001
- In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJournal of Antimicrobial Chemotherapy, 1999
- Gram-positive resistance: challenge for the development of new antibioticsJournal of Antimicrobial Chemotherapy, 1997
- Nomenclature of TEM beta-lactamasesJournal of Antimicrobial Chemotherapy, 1997